TherapeuticsMD, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands)
| Common Stock · Additional Paid in · Accumulated | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Total | |
| Balance, December 31, 2022 | 9,498 | $9 | $974,497 | $(939,363) | $35,143 |
| Shares issued for vested restricted stock units | 844 | 1 | — | — | 1 |
| Share-based compensation | — | — | 1,271 | — | 1,271 |
| Shares issued for sale of common stock related to private placement sale | 1,190 | 1 | 3,149 | — | 3,150 |
| Net loss | — | — | — | (10,278) | (10,278) |
| Balance, December 31, 2023 | 11,532 | 11 | 978,917 | (949,641) | 29,287 |
| Share-based compensation | — | — | 264 | — | 264 |
| Net loss | — | — | — | (2,181) | (2,181) |
| Balance, December 31, 2024 | 11,532 | $11 | $979,181 | $(951,822) | $27,370 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.